Why did Novavax stock go down today?
- BySeeking Alpha-
After back-to-back sessions of gains, the shares of COVID-19 vaccine developer Novavax (NVAX) are back on the decline.While many COVID-19 vaccine developers are in the red...
After back-to-back sessions of gains, the shares of COVID-19 vaccine developer Novavax (NVAX) are back on the decline.While many COVID-19 vaccine developers are in the red...
Ocugen Inc. (NASDAQ: OCGN) shares were trading higher Tuesday after the Indian government approved Bharat Biotech’s COVID-19 vaccine Covaxin, for children between the ages of 2 and...
Coronavirus Update: U.S. daily new-case tally moves below 100,000 mark
Vaccine makers have been under tremendous selling pressure over the past 2 months driven by policy, the rising delta wave, and breakthrough infections. This slump has been a boost...
The COVID-19 vaccine market in developed economies is dominated by the likes of Pfizer (PFE) and Moderna (MRNA). These companies have benefitted from an early-mover...
Monday the US stock market moved into further robust mode fueled by official FDA approval of the Pfizer and BioNTech COVID-19 vaccines. Will the momentum last through to Thursday...
Type | 5 Min | 15 Min | Hourly | Daily | Monthly |
|---|---|---|---|---|---|
| Moving Averages | Strong Sell | Strong Sell | Strong Sell | Strong Sell | Buy |
| Technical Indicators | Strong Sell | Strong Sell | Strong Sell | Strong Sell | Sell |
| Summary | Strong Sell | Strong Sell | Strong Sell | Strong Sell | Neutral |
Name | Last | High | Low | Chg. | Chg. % | Vol. | Time | ||
|---|---|---|---|---|---|---|---|---|---|
| 432.10 | 434.10 | 430.00 | -0.70 | -0.16% | 15.77M | London | |||
| 33.38 | 33.62 | 33.08 | +0.30 | +0.91% | 4.06M | London | |||
| 3,885.00 | 3,905.00 | 3,825.00 | -5.0 | -0.13% | 23.43K | London | |||
| 198.60 | 205.50 | 196.60 | -2.40 | -1.19% | 294.66K | London | |||
| 321.60 | 329.20 | 320.40 | -8.40 | -2.54% | 201.81K | London | |||
| 373.60 | 398.60 | 373.00 | -21.20 | -5.37% | 1.14M | London | |||
| 372.80 | 377.20 | 367.60 | +3.40 | +0.92% | 475.67K | London | |||
| 52.08 | 53.04 | 51.18 | +0.46 | +0.89% | 7.70M | London | |||
| 317.60 | 328.80 | 315.80 | -4.40 | -1.37% | 1.09M | London | |||
| 64.74 | 65.72 | 64.58 | -0.18 | -0.28% | 3.23M | London | |||
| 49.40 | 49.48 | 49.00 | +0.12 | +0.25% | 113.21M | London | |||
| 880.00 | 884.00 | 878.00 | +2.00 | +0.23% | 370.90K | London | |||
| 1,830.00 | 1,859.50 | 1,829.50 | -6.5 | -0.35% | 658.93K | London | |||
| 139.44 | 142.98 | 138.58 | -3.20 | -2.24% | 49.20M | London | |||
| 3,606.50 | 3,627.50 | 3,593.50 | -1.0 | -0.03% | 2.43M | London |
Novavax, Inc. is a clinical-stage vaccine company focused on the discovery, development and commercialization of recombinant nanoparticle vaccines and adjuvants. The Company operates through developing recombinant vaccines segment. The Company, through its recombinant nanoparticle vaccine technology, produces vaccine candidates to respond to both known and newly emerging diseases. The Company's product pipeline focuses on a range of infectious diseases with vaccine candidates in clinical development for respiratory syncytial virus (RSV), seasonal influenza, pandemic influenza and the Ebola virus (EBOV). The Company's lead adjuvant for human applications, Matrix-M, is in a Phase I/II clinical trial for pandemic influenza H7N9 vaccine candidate. It is also testing Matrix-M in conjunction with its EBOV vaccine candidate in a Phase I clinical trial. It is developing additional pre-clinical stage programs in a range of infectious diseases, including Middle East respiratory syndrome (MERS).